CN115501390A - Skin beautifying compound injection and preparation method thereof - Google Patents
Skin beautifying compound injection and preparation method thereof Download PDFInfo
- Publication number
- CN115501390A CN115501390A CN202211275825.5A CN202211275825A CN115501390A CN 115501390 A CN115501390 A CN 115501390A CN 202211275825 A CN202211275825 A CN 202211275825A CN 115501390 A CN115501390 A CN 115501390A
- Authority
- CN
- China
- Prior art keywords
- injection
- polysaccharide
- polylactic acid
- percent
- graft copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 62
- 239000007924 injection Substances 0.000 title claims abstract description 62
- 150000001875 compounds Chemical class 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 47
- 239000004626 polylactic acid Substances 0.000 claims abstract description 47
- 229920000578 graft copolymer Polymers 0.000 claims abstract description 40
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 26
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 26
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 26
- 239000002131 composite material Substances 0.000 claims abstract description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000693 micelle Substances 0.000 claims abstract description 6
- 230000005855 radiation Effects 0.000 claims description 19
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 5
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 230000003796 beauty Effects 0.000 abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000037303 wrinkles Effects 0.000 abstract description 5
- 239000007857 degradation product Substances 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 230000035515 penetration Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical group CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- RKQOSDAEEGPRER-UHFFFAOYSA-L zinc diethyldithiocarbamate Chemical compound [Zn+2].CCN(CC)C([S-])=S.CCN(CC)C([S-])=S RKQOSDAEEGPRER-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a skin beautifying composite injection and a preparation method thereof, belonging to the technical field of beauty. The skin beautifying composite injection consists of the following components in percentage by mass: 0 to 25 percent of hyaluronic acid, 1 to 25 percent of polysaccharide-polylactic acid graft copolymer, 0 to 5 percent of mannitol and 45 to 99 percent of water solution for injection. The skin beautifying composite injection disclosed by the invention is prepared by adding the polysaccharide-polylactic acid graft copolymer serving as a component into the hyaluronic acid injection, wherein the polysaccharide-polylactic acid graft copolymer exists in a sol or micelle form, and can stimulate cells to generate collagen by using a degradation product lactic acid while keeping the needle penetration property, so that the long-acting wrinkle removing function is realized, and the skin beautifying composite injection is an iteration of the existing hyaluronic acid injection beautifying product.
Description
Technical Field
The invention relates to a skin beautifying composite injection and a preparation method thereof, belonging to the technical field of beauty.
Background
With age, human skin undergoes collagen loss and cell aging, resulting in the production of wrinkles. Subcutaneous injection of hyaluronic acid and its salts can engorge skin tissue, remove wrinkles and fill skin contours. However, hyaluronic acid and its salts do not stimulate collagen production by skin cells and have a limited duration of action, requiring repeated injections.
In recent years, graft copolymers have been developed rapidly, and natural polysaccharides such as dextran, chitosan, hyaluronic acid, etc. can be formed into graft copolymers with polylactic acid by various chemical synthesis methods. The polysaccharide-polylactic acid graft copolymer has good biocompatibility, can be degraded in a human body, and degradation products are non-toxic, and in addition, as an amphiphilic polymer, the polysaccharide-polylactic acid graft copolymer can form micelles or hydrogel, so that the polysaccharide-polylactic acid graft copolymer can be widely applied to the field of biological medicines as a drug delivery carrier. At present, the application of the polysaccharide-polylactic acid graft copolymer in the aspect of beautifying and wrinkle removal is not found.
Disclosure of Invention
The invention aims to provide a skin beautifying compound injection capable of stimulating cells to produce collagen.
The skin beautifying composite injection consists of the following components in percentage by mass:
0 to 25 percent of hyaluronic acid, 1 to 25 percent of polysaccharide-polylactic acid graft copolymer, 0 to 5 percent of mannitol and 45 to 99 percent of water solution for injection.
The sum of the mass percentages of the components is 100 percent.
Preferably, the injection consists of the following components in percentage by mass: 1 to 20 percent of hyaluronic acid, 10 to 25 percent of polysaccharide-polylactic acid graft copolymer, 0.1 to 5 percent of mannitol and 55 to 88.9 percent of water solution for injection.
In the skin beautifying composite injection, the polysaccharide-polylactic acid graft copolymer exists in the form of sol or micelle in the injection.
Preferably, the polysaccharide in the polysaccharide-polylactic acid graft copolymer is glucan, chitosan or hyaluronic acid, and the molecular weight of a polysaccharide chain segment is any value between 1 and 100 kDa.
Preferably, the polylactic acid segment in the polysaccharide-polylactic acid graft copolymer is PLLA or PDLLA, and the molecular weight of the polylactic acid segment is any value between 1 and 50 kDa.
In the skin beautifying composite injection, the polysaccharide-polylactic acid graft copolymer can be synthesized by various methods disclosed by the prior art, for example, direct polymerization of lactic acid directly initiated by polysaccharide (Wu Jingmei and the like, preparation and characterization of chitosan-polylactic acid graft copolymer, novel chemical materials, 2012.40), lactide ring-opening grafting (Cai Qing and the like, research on synthesis and in-vitro degradation behaviors of polylactic acid graft glucan copolymer, published by high molecular report, 2004.5), end group reaction grafting (Yuan Hua and the like, preparation and characterization of chitosan-polylactic acid graft copolymer, high molecular material science and engineering, 2009.25) and the like.
Preferably, the molecular weight of the hyaluronic acid is any value between 10 and 100 kDa.
Preferably, the aqueous solution for injection is physiological saline or phosphate buffer
The invention also aims to provide a preparation method of the skin beautifying compound injection.
A skin caring compound injection is prepared by stirring hyaluronic acid, polysaccharide-polylactic acid graft copolymer, mannitol, and injectable water solution to obtain uniform mixed solution; subpackaging the mixed solution, and performing radiation sterilization to obtain the skin beautifying compound injection.
Preferably, the radiation sterilization mode is Co 60 Sterilizing by radiation, wherein the radiation dose is any value of 7-10 kGy.
The beneficial effects of the invention are as follows: the skin beautifying composite injection disclosed by the invention is prepared by adding the polysaccharide-polylactic acid graft copolymer serving as a component into the hyaluronic acid injection, wherein the polysaccharide-polylactic acid graft copolymer exists in a sol or micelle form, and can stimulate cells to generate collagen by using a degradation product lactic acid while keeping the needle penetration property, so that the long-acting wrinkle removing function is realized, and the skin beautifying composite injection is an iteration of the existing hyaluronic acid injection beautifying product.
Drawings
Fig. 1 shows the appearance of the skin beautifying compound injection prepared in example 1 of the present invention.
Detailed Description
The following non-limiting examples are presented to enable those of ordinary skill in the art to more fully understand the present invention and are not intended to limit the invention in any way.
The test methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials are commercially available, unless otherwise specified.
One of the specific implementation modes is as follows:
a skin caring compound injection comprises hyaluronic acid, polysaccharide-polylactic acid graft copolymer, mannitol, and injectable aqueous solution.
The molecular weight of the hyaluronic acid is any value between 10 and 100 kDa. The mass percentage of the hyaluronic acid is any value in the range of 0-25%.
The polysaccharide-polylactic acid graft copolymer comprises, but is not limited to, dextran, chitosan, hyaluronic acid and the like. The polysaccharide-polylactic acid graft copolymer has a polysaccharide chain segment with a molecular weight of 1-100 kDa. The polysaccharide-polylactic acid graft copolymer has any value in the range of 1-25% by mass.
The polylactic acid chain segment of the polysaccharide-polylactic acid graft copolymer comprises PLLA and PDLLA. The polysaccharide-polylactic acid graft copolymer has a polylactic acid chain segment with a molecular weight of 1-50 kDa. The polysaccharide-polylactic acid graft copolymer has any value in the range of 1-25% by mass.
The mannitol is in any value within the range of 0-5% by mass.
The water solution for injection is normal saline or phosphate buffer solution, and the mass percentage content of the water solution for injection is any value in the range of 45-99%.
The invention provides a preparation method of a skin beautifying compound injection capable of stimulating cells to produce collagen, which comprises the following steps: hyaluronic acid, polysaccharide-polylactic acid graft copolymer, mannitol and water solution for injection are fully stirred to obtain uniform mixed solution. Subpackaging the mixed solution, and performing radiation sterilization to obtain the skin beautifying composite injection.
The polysaccharide-polylactic acid graft copolymer exists in the form of sol or micelle in injection.
The radiation sterilization adopts Co 60 Radiation of radiationSterilizing, and irradiating with any value of 7-10 kGy.
In the following examples, the polysaccharide-polylactic acid graft copolymer was prepared as follows:
adding primary hydroxyl polylactic acid (PLLA-OH) and N, N-dicyclohexylcarbodiimide with specific molecular weight into dimethyl sulfoxide (DMSO) according to a molar ratio of 1:1 at room temperature, precipitating the solution with absolute ethyl alcohol after 20h, centrifugally separating the obtained precipitate, and carrying out vacuum drying after decompression and suction filtration of the precipitate part to obtain a white powdery solid product. Dispersing a certain amount of polysaccharide in DMSO, adding PLLA-CHO (the molar ratio of the polysaccharide to the polysaccharide is 1.
Example 1
A method for preparing skin beauty compound injection capable of stimulating cells to produce collagen comprises the following steps:
1.0g of dextran-polylactic acid graft copolymer (Dex) 6000 -PLLA 4000 ) 0.2g of hyaluronic acid (molecular weight: 100000), 0.25g of mannitol and 10mL of physiological saline for injection were thoroughly mixed. After completely dissolving uniformly, co is adopted 60 Radiation sterilization is carried out, and the radiation dose is 7kGy. And sterilizing to obtain the skin beautifying composite injection.
Example 2
A method for preparing skin beauty compound injection capable of stimulating cells to produce collagen comprises the following steps:
0.1g of hyaluronic acid-polylactic acid graft copolymer (HA) 40000 -PLLA 10000 ) 0.5g of hyaluronic acid (molecular weight: 100000) was thoroughly mixed with 9.5mL of physiological saline for injection. After completely dissolving uniformly, co is adopted 60 Radiation sterilization is carried out, and the radiation dose is 7kGy. And sterilizing to obtain the skin beautifying composite injection.
Example 3
A method for preparing skin beauty compound injection capable of stimulating cells to produce collagen comprises the following steps:
1.0gChitosan-polylactic acid graft Copolymer (CS) 6500 -PDLLA 6000 ) 0.1g hyaluronic acid (molecular weight 200000), 0.1g mannitol and 10mL injection physiological saline fully mixed. After completely dissolving uniformly, co is adopted 60 Sterilizing by radiation, and the radiation dose is 10kGy. Sterilizing to obtain the skin beautifying compound injection.
Example 4
A method for preparing skin beauty compound injection capable of stimulating cells to produce collagen comprises the following steps:
2.0g of chitosan-polylactic acid graft Copolymer (CS) 10000 -PDLLA 50000 ) Mixed well with 8mL of physiological saline for injection. After the mixture is completely and uniformly dissolved, co is adopted 60 Sterilizing by radiation, and the radiation dose is 10kGy. Sterilizing to obtain the skin beautifying compound injection.
Cytotoxicity was measured by MTT assay for examples 1 to 4.
Cytotoxicity reference GB/T16886.5-2017 medical device biology evaluation part 5: in vitro cytotoxicity test examine the survival of cells after different groups of cosmetic injections are added. And (3) converting the relative cell proliferation rate into 5-grade reaction to evaluate the toxicity of the sample, wherein the negative control is PBS, and the positive control is zinc diethyldithiocarbamate.
TABLE 1 cytotoxicity test results
| Group of | Increment rate | Toxicity rating |
| Negative control | 100％ | Level 0 |
| Example 1 | 96.5％ | Level 1 |
| Example 2 | 95.7％ | Level 1 |
| Example 3 | 97.3％ | Level 1 |
| Example 4 | 95.2％ | Level 1 |
| Positive control | 18.7％ | 4 stage |
Claims (9)
1. The skin beautifying composite injection is characterized by comprising the following components in percentage by mass:
0 to 25 percent of hyaluronic acid, 1 to 25 percent of polysaccharide-polylactic acid graft copolymer, 0 to 5 percent of mannitol and 45 to 99 percent of water solution for injection.
2. The injection according to claim 1, which consists of the following components in percentage by mass: 1 to 20 percent of hyaluronic acid, 10 to 25 percent of polysaccharide-polylactic acid graft copolymer, 0.1 to 5 percent of mannitol and 55 to 88.9 percent of water solution for injection.
3. The injection according to claim 1, wherein the polysaccharide-polylactic acid graft copolymer exists in the form of sol or micelle in the injection.
4. The injection according to claim 1, wherein the polysaccharide in the polysaccharide-polylactic acid graft copolymer is dextran, chitosan or hyaluronic acid, and the molecular weight of the polysaccharide segment is any value between 1-100 kDa.
5. The injection according to claim 1, wherein the polylactic acid segment of the polysaccharide-polylactic acid graft copolymer is PLLA or PDLLA, and the molecular weight of the polylactic acid segment is any value between 1 and 50 kDa.
6. The injection according to claim 1, wherein the molecular weight of the hyaluronic acid is any value between 10 and 100 kDa.
7. The injection according to claim 1, wherein the aqueous solution for injection is physiological saline or phosphate buffer.
8. A method for preparing the skin beautifying compound injection as claimed in any one of claims 1 to 7, characterized by comprising the following steps: fully stirring hyaluronic acid, polysaccharide-polylactic acid graft copolymer, mannitol and water solution for injection to obtain uniform mixed solution; subpackaging the mixed solution, and performing radiation sterilization to obtain the skin beautifying compound injection.
9. The method of claim 8, wherein the radiation sterilization is performed by Co 60 Sterilizing by radiation, wherein the radiation dose is any value of 7-10 kGy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211275825.5A CN115501390A (en) | 2022-10-18 | 2022-10-18 | Skin beautifying compound injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211275825.5A CN115501390A (en) | 2022-10-18 | 2022-10-18 | Skin beautifying compound injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115501390A true CN115501390A (en) | 2022-12-23 |
Family
ID=84510169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211275825.5A Pending CN115501390A (en) | 2022-10-18 | 2022-10-18 | Skin beautifying compound injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115501390A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116832213A (en) * | 2023-07-11 | 2023-10-03 | 杭州帕莱拉医疗科技有限公司 | Preparation method of injectable dextran/poly-L-lactic acid interpenetrating network microsphere composite hydrogel filler |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160175342A1 (en) * | 2013-08-09 | 2016-06-23 | Genbiotech | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same |
| KR102051467B1 (en) * | 2019-06-12 | 2019-12-03 | 박상준 | Skin filler composition and method for manufacturing the same |
| CN110638676A (en) * | 2019-09-30 | 2020-01-03 | 西安博和医疗科技有限公司 | Hyaluronic acid injection and preparation method thereof |
| CN111249172A (en) * | 2020-01-15 | 2020-06-09 | 陈勇 | Beauty injection gel and preparation method thereof |
| CN113663059A (en) * | 2021-08-31 | 2021-11-19 | 苏州姑苏欣颜魅丽医疗美容诊所有限公司 | Anti-aging beauty injection and preparation method thereof |
| CN113730652A (en) * | 2021-09-01 | 2021-12-03 | 北京大清生物技术股份有限公司 | Mixed gel for injection and preparation method and application thereof |
| CN114699554A (en) * | 2021-12-20 | 2022-07-05 | 南京思元医疗技术有限公司 | Injection for correcting skin wrinkles for medical cosmetology and preparation method thereof |
| CN114948790A (en) * | 2021-04-06 | 2022-08-30 | 郑州欧华医疗美容医院有限公司 | Rainbow water-light composite skin-beautifying formula |
-
2022
- 2022-10-18 CN CN202211275825.5A patent/CN115501390A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160175342A1 (en) * | 2013-08-09 | 2016-06-23 | Genbiotech | Continuous release compositions made from hyaluronic acid, and therapeutic applications of same |
| KR102051467B1 (en) * | 2019-06-12 | 2019-12-03 | 박상준 | Skin filler composition and method for manufacturing the same |
| CN110638676A (en) * | 2019-09-30 | 2020-01-03 | 西安博和医疗科技有限公司 | Hyaluronic acid injection and preparation method thereof |
| CN111249172A (en) * | 2020-01-15 | 2020-06-09 | 陈勇 | Beauty injection gel and preparation method thereof |
| CN114948790A (en) * | 2021-04-06 | 2022-08-30 | 郑州欧华医疗美容医院有限公司 | Rainbow water-light composite skin-beautifying formula |
| CN113663059A (en) * | 2021-08-31 | 2021-11-19 | 苏州姑苏欣颜魅丽医疗美容诊所有限公司 | Anti-aging beauty injection and preparation method thereof |
| CN113730652A (en) * | 2021-09-01 | 2021-12-03 | 北京大清生物技术股份有限公司 | Mixed gel for injection and preparation method and application thereof |
| CN114699554A (en) * | 2021-12-20 | 2022-07-05 | 南京思元医疗技术有限公司 | Injection for correcting skin wrinkles for medical cosmetology and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 纪风涛;曹铭辉;毛鹏;樊碧发;梁建军;苗利萍;: "葡聚糖接枝聚乳酸载吗啡缓释纳米粒胶束对急性疼痛大鼠的镇痛效应", 中国疼痛医学杂志, no. 04, pages 232 - 235 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116832213A (en) * | 2023-07-11 | 2023-10-03 | 杭州帕莱拉医疗科技有限公司 | Preparation method of injectable dextran/poly-L-lactic acid interpenetrating network microsphere composite hydrogel filler |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI789338B (en) | Use of an in situ cross-linkable polysaccharide composition, a multi-barrel syringe system associating with the same, a combination of derivatives for forming the in situ cross-linkable polysaccharide composition and a kit for forming the in situ cross-linkable polysaccharide composition | |
| US20180362670A1 (en) | Method for manufacturing a shaped crosslinked hyaluronic acid product | |
| JP6106686B2 (en) | Water-insoluble gel composition and method for producing the same | |
| US11866556B2 (en) | Process for efficient cross-linking of hyaluronic acid | |
| HUE026830T2 (en) | Viscoelastic gels as novel fillers | |
| KR20140059238A (en) | Injectable filler | |
| KR101356320B1 (en) | A long-lasting injectable hyraluronic acid dermal filler developed by pullulan microsphere | |
| CN101036808A (en) | Cross-linked hyaluronic acid derivatives preparation and the preparing technique | |
| FR2873379A1 (en) | PROCESS FOR PREPARING RETICULATED HYALURONIC ACID, RETICULATED HYALURONIC ACID WHICH CAN BE OBTAINED THEREBY, IMPLANT CONTAINING SAID RETICULATED HYALURONIC ACID, AND USE THEREOF | |
| KR20210021362A (en) | Hydrogel composition containing crosslinked polymer | |
| TW202041221A (en) | Modified hyaluronic acid derivative and method for preparing same, applications thereof, use thereof, crosslinked hydrogel and method for preparing same, kit for the in situ formation thereof | |
| CN115501390A (en) | Skin beautifying compound injection and preparation method thereof | |
| La Gatta et al. | Hyaluronan-based hydrogels via ether-crosslinking: Is HA molecular weight an effective means to tune gel performance? | |
| KR100812824B1 (en) | Biocompatible low toxicity film using chitosan and polyethylene glycol | |
| EP4063433A1 (en) | Hydrogel of mercapto-modified macromolecular compound, and preparation method therefor and use thereof | |
| CN106999626B (en) | Biocompatible compositions and methods of preparation | |
| KR20210021361A (en) | Hydrogel composition containing crosslinked polymer | |
| CN117500535A (en) | Cross-linking polysaccharides with fibroin and use of the obtained material | |
| CN106714856B (en) | Composition containing glycosaminoglycan and protein | |
| KR20170100746A (en) | hyraluronic acid dermal filler | |
| KR20170105212A (en) | A long-lasting injectable hyraluronic acid dermal filler developed by pullulan microsphere | |
| Samanipour et al. | Injectable Collagen/CMC soft tissue filler with developed flow properties | |
| KR102684411B1 (en) | Dermal filler composition containing hyaluronic acid cross-linked by sulfosuccinic acid and biocompatible micro particles, and Method for preparing the same | |
| KR102684409B1 (en) | Dermal filler composition containing hyaluronic acid cross-linked by succinic acid and Method for preparing the same | |
| KR100880899B1 (en) | A biodegradable material having controlled molecular weight prepared by irradiating ion beam, and a process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |